Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Ernesto Sparrelid

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0259-8328; OpenAlex author ID A5032951554. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
140
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 7 papers · 2026: 6 papers

Papers 20

  1. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  2. Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2025.106024↗
  3. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  4. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  5. Multiple R1 margins are associated with shorter overall survival: national register-based study on pancreatic cancer. Co-author DOI 10.1093/bjsopen/zrag155↗
  6. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  7. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  8. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  9. Pancreatic cancer risk after benign gallbladder disease: A Swedish population-based cohort study. Co-author DOI 10.1016/j.ejca.2024.115140↗
  10. An injury-associated lobular microniche is associated with the classical tumor cell phenotype in pancreatic cancer. Co-author DOI 10.1038/s41467-025-63864-7↗
  11. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  12. Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. Co-author DOI 10.1186/s12893-025-02983-w↗
  13. Assessment of Outcomes by Intention-to-Treat Comparison for Locally Advanced Pancreatic Cancer: A Population-Derived Cohort Study. Co-author DOI 10.1245/s10434-024-16291-9↗
  14. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Co-author DOI 10.1080/00365521.2024.2378948↗
  15. Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0405↗
  16. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide re… Last author DOI 10.1016/j.pan.2022.12.003↗
  17. Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Tr… Co-author DOI 10.2967/jnumed.123.265481↗
  18. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal ad… Last author DOI 10.1016/j.pan.2022.04.007↗
  19. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to … Last author DOI 10.1016/j.suronc.2022.101735↗
  20. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2021.07.009↗

Closest collaborators

The 25 strongest of 140 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Poya Ghorbani · 12 shared papers, 2021–2026 · strength 2.52
  2. Asif Halimi · 6 shared papers, 2024–2026 · strength 1.12
  3. Patrik Larsson · 4 shared papers, 2025–2026 · strength 1.00
  4. Carlos Fernández Moro · 4 shared papers, 2024–2026 · strength 1.00
  5. Matthias J. Löhr · 5 shared papers, 2021–2024 · strength 0.92
  6. Marco Del Chiaro · 5 shared papers, 2021–2026 · strength 0.86
  7. Geert Kazemier M · 4 shared papers, 2026 · strength 0.78
  8. Marcus Holmberg · 4 shared papers, 2021–2023 · strength 0.73
  9. Ingmar Florin Rompen · 4 shared papers, 2025–2026 · strength 0.71
  10. Bas Groot Koerkamp · 4 shared papers, 2025–2026 · strength 0.71
  11. Thomas F. Stoop · 4 shared papers, 2025–2026 · strength 0.71
  12. Marc G. Besselink · 4 shared papers, 2025–2026 · strength 0.71
  13. Ammar A. Javed · 4 shared papers, 2025–2026 · strength 0.71
  14. Elena B. Rangelova · 3 shared papers, 2024–2026 · strength 0.62
  15. Cecilia Radkiewicz · 2 shared papers, 2023–2025 · strength 0.57
  16. Freek D. Daams · 3 shared papers, 2026 · strength 0.56
  17. Oskar Franklin · 3 shared papers, 2026 · strength 0.56
  18. Roeland F. de Wilde · 3 shared papers, 2026 · strength 0.56
  19. Christopher Lee Wolfgang · 3 shared papers, 2026 · strength 0.56
  20. Richard David Schulick · 3 shared papers, 2026 · strength 0.56
  21. Bobby Tingstedt · 2 shared papers, 2024–2026 · strength 0.52
  22. Kjetil Søreide · 2 shared papers, 2024–2025 · strength 0.44
  23. Jorg H. Kleeff · 2 shared papers, 2025–2026 · strength 0.40
  24. Per Pfeiffer · 2 shared papers, 2025–2026 · strength 0.40
  25. Michael Bau Mortensen · 2 shared papers, 2025–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.